Potentially hazardous eye care products recalled nationwide

News
Article

BRS Analytical Service, LLC, an independent contract testing laboratory, initiated the recall because of possible concerns about product quality and safety linked to the manufacturing process. An FDA audit revealed serious manufacturing violations of Current Good Manufacturing Practice.

Voluntary recall for potentially hazardous eye drops - Image credit:©Kwangmoozaa—stock.adobe.com

The FDA gave its second-highest warning rating (a Class II risk) to five ophthalmic solutions because of violations of current manufacturing practices.

(Image credit: ©Kwangmoozaa—stock.adobe.com)

A voluntary product recall issued on May 12 stated several eye care products have been recalled nationwide due to potential safety risks. More than 70,000 items have been recalled in the US.

BRS Analytical Service, LLC, an independent contract testing laboratory, initiated the recall because of possible concerns about product quality and safety linked to the manufacturing process. An FDA audit revealed serious manufacturing violations of Current Good Manufacturing Practice.

The FDA gave its second-highest warning rating (a Class II risk) to five ophthalmic solutions because of violations of current manufacturing practices. The products involved are as follows:

  • Artificial Tears Ophthalmic Solution (NDC# 50268-043-15)
  • Carboxymethylcellulose Sodium Ophthalmic Gel 1% (NDC# 50268-066-15)
  • Carboxymethylcellulose Sodium Ophthalmic Solution (NDC# 50268-068-15)
  • Lubricant Eye Drops Solution (NDC# 50268-126-15)
  • Polyvinyl Alcohol Ophthalmic Solution (NDC# 50268-678-15)

This risk level is defined as “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

No specific health hazards were mentioned, but the deviations from the Current Good Manufacturing Practice may result in “products of unacceptable quality” and risks to patients could not be ruled out completely.

All of these products were distributed by AvKARE, of Pulaski, TN, and all were distributed between May 26, 2023, and April 21, 2025. Consumers were advised to stop using the products and to return them.

AvKARE stated, "We will issue full credit including shipping cost for any returns.”

Customers are instructed to complete the “Quantity to Return” section on the recall notice and email it to customerservice@avkare.com or fax it to 931-292-6229, even if they no longer possess the product.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Brett Bielory, MD, at ASCRS 2025
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Dr Ben Gaddie chats about his dry eye presentation at SECO and ocular surface disease.jpg
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
© 2025 MJH Life Sciences

All rights reserved.